Back to top
more

Abbott Laboratories (ABT)

(Real Time Quote from BATS)

$131.14 USD

131.14
2,193,838

+0.45 (0.34%)

Updated Aug 6, 2025 01:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Urmimala Biswas headshot

CGM Devices Gain Steam, Set New Trend in Diabetes Management

by Urmimala Biswas

The FDA authorization classifies the new type of CGM devices in class II and subjects these to certain criteria called special controls.

Zacks Equity Research

Abbott Receives European Nod for Pediatric Heart Devices

by Zacks Equity Research

Abbott (ABT) aims to offer better treatment options for the most vulnerable patient population.

Zacks Equity Research

Abbott Partners With Sanofi to Upgrade Diabetes Management

by Zacks Equity Research

Abbott (ABT) collaborates with Sanofi to revolutionize diabetes care through technological advancements.

Zacks Equity Research

Abbott (ABT) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Abbott (ABT) closed at $83.36 in the latest trading session, marking a -1.08% move from the prior day.

Zacks Equity Research

Abbott's (ABT) FreeStyle Libre Gains Canadian Reimbursement

by Zacks Equity Research

With this reimbursement approval, Abbott's (ABT) FreeStyle Libre becomes the first sensor-based glucose monitoring system to be listed by any provincial health plan in Canada.

Zacks Equity Research

Abbott Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Abbott Laboratories has been struggling lately, but the selling pressure may be coming to an end soon.

Zacks Equity Research

Abbott (ABT) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Abbott (ABT) closed at $83.19, marking a -1.22% move from the previous day.

Zacks Equity Research

Abbott (ABT) Launches Pivotal Trial TRILUMINATE in the US

by Zacks Equity Research

Given the lack of an alternative therapy to replace tricuspid regurgitation surgery, Abbott (ABT) should be at an advantage in this space.

Zacks Equity Research

Here's Why You Should Hold on to Thermo Fisher (TMO) for Now

by Zacks Equity Research

Investors continue to be optimistic about Thermo Fisher's (TMO) performance.

Zacks Equity Research

5 Cancer-Fighting Stocks to Add to Your Portfolio

by Zacks Equity Research

Cancer-fighting stocks receive a boost from advance research and development. These five stocks can add value to your portfolio.

Zacks Equity Research

Abbott (ABT) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Abbott (ABT) closed the most recent trading day at $84.22, moving +0.68% from the previous trading session.

Zacks Equity Research

Here's Why You Should Add Abbott (ABT) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Abbott (ABT) on its balanced segmental performances.

Zacks Equity Research

Abbott's (ABT) TRACK-TBI Study Reveals Encouraging Results

by Zacks Equity Research

This study outcome should be a crucial step forward for Abbott Laboratories (ABT) in its endeavor to boost TBI diagnosis and treatment.

Zacks Equity Research

Has Abbott Laboratories (ABT) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (ABT) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Abbott (ABT) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Abbott (ABT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Abbott (ABT) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Abbott (ABT) closed the most recent trading day at $84.37, moving -0.62% from the previous trading session.

Zacks Equity Research

Abbott's Libre Adoption a Positive, Rhythm Management a Woe

by Zacks Equity Research

Abbott (ABT) is steadily riding high on a healthy growth track within its Diabetes Care business.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Home Depot, Abbott, Bristol-Myers, Activision and Marathon

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Home Depot, Abbott, Bristol-Myers, Activision and Marathon

Zacks Equity Research

Tandem Diabetes Rides on t:slim X2 Uptake, Product Pipeline

by Zacks Equity Research

Robust domestic sales along with a strong unveiling of the t:slim X2 Insulin Pump in the international markets augur well for Tandem Diabetes (TNDM).

Zacks Equity Research

FDA OKs Medtronic's Evolut TAVR New Indication for Low Risk

by Zacks Equity Research

With the FDA's expanded indication nod, Medtronic's (MDT) Evolut TAVR platform now comes in handy for treating symptomatic severe aortic stenosis patients across all risk categories.

Mark Vickery headshot

Top Stock Reports for Home Depot, Abbott & Bristol-Myers

by Mark Vickery

Today's Research Daily features updated research reports on 16 major stocks, including Home Depot (HD), Abbott (ABT) and Bristol-Myers (BMY).

Zacks Equity Research

Here's Why You Should Hold Onto IDEXX (IDXX) Stock for Now

by Zacks Equity Research

Investor confidence continues to be high on IDEXX Laboratories' (IDXX) prospects.

Zacks Equity Research

Abbott (ABT) Down 4.4% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Zacks.com featured highlights include: Abbott Laboratories, Baxter International, First Horizon National, OUTFRONT Media and ICF International

by Zacks Equity Research

Zacks.com featured highlights include: Abbott Laboratories, Baxter International, First Horizon National, OUTFRONT Media and ICF International

Zacks Equity Research

5 Stocks Trading Near 52-Week High With More Room to Run

by Zacks Equity Research

Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.